Skip to Content
Merck
All Photos(1)

Documents

N-007

Supelco

Naltrexone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H23NO4
CAS Number:
16590-41-3
Molecular Weight:
341.40
MDL number:
MFCD00242996
UNSPSC Code:
41116107
PubChem Substance ID:
329818395
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

shipped in

wet ice

storage temp.

2-8°C

SMILES string

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC6CC6

InChI

1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1

InChI key

DQCKKXVULJGBQN-XFWGSAIBSA-N

Gene Information

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Related Categories

General description

Naltrexone is an opiate sold under the trade names Revia, Depade and Vivitrol® and is prescribed primarily for the management of alcohol or opiate dependence. This analytical reference standard is applicable for use in LC/MS or GC/MS applications such as pharmaceutical research, forensic analysis, clinical toxicology, pain prescription monitoring or urine drug testing.

Application


  • Naltrexone research solution: Research utilizes naltrexone in thermosensitive gels to enhance microneedle-assisted transdermal delivery, showcasing its potential for non-invasive therapeutic applications and improving drug bioavailability (Polymers (Basel), 2021; doi: 10.3390/polym13060933).

  • Opioid receptor antagonist: A study discusses the historical context of opioid use disorder trials, with naltrexone featured as a pivotal medication in optimizing treatment strategies. This research underscores its importance in addiction studies and the development of effective treatment modalities (Addict Sci Clin Pract, 2021; doi: 10.1186/s13722-021-00223-z).

  • Naltrexone in vitro study: The compound is utilized in a model of ocular neuropathic pain, highlighting its utility in pain management research and its potential role in developing new therapeutic strategies for chronic pain conditions (Transl Vis Sci Technol, 2019; doi: 10.1167/tvst.8.2.6).

  • Naltrexone pharmacological research: Research on Mg²⁺ influx modulation in cardiac myocytes provides insights into ionic exchanges in heart tissues, demonstrating naltrexone′s broader applications in physiological and pharmacological studies (J Physiol Sci, 2019; doi: 10.1007/s12576-018-0625-5).

  • Naltrexone biochemistry application: A study explores mechanical stimulation for reducing ethanol self-administration in rats, indicating naltrexone′s utility in experimental models of addiction and its potential application in behavioral sciences (Evid Based Complement Alternat Med, 2017; doi: 10.1155/2017/6578621).

Recommended products

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vivitrol is a registered trademark of Alkermes, Inc.

related product

Product No.
Description
Pricing

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

IMPN-007-02

10-Hydroxynaltrexone solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPN-007-03

10-Ketonaltrexone solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-038

6β-Naltrexol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-047

Naltrexone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-081

6β-Naltrexol-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-227

Methylnaltrexone bromide solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

M-228

Methylnaltrexone-D3 bromide solution, 100 μg/mL in methanol ((as quarternary ammonium ion)), certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Treatment of comorbid substance dependence and posttraumatic stress disorder.
Katherine Mills
JAMA, 310(5), 482-483 (2013-08-09)
Edna B Foa et al.
JAMA, 310(5), 488-495 (2013-08-09)
Alcohol dependence comorbid with posttraumatic stress disorder (PTSD) has been found to be resistant to treatment. In addition, there is a concern that prolonged exposure therapy for PTSD may exacerbate alcohol use. To compare the efficacy of an evidence-based treatment
Arnt Schellekens
Nederlands tijdschrift voor geneeskunde, 157(23), A5725-A5725 (2013-06-07)
This article describes the current scientific knowledge regarding pharmacogenetic predictors of treatment outcome for substance-dependent patients. PubMed was searched for articles on pharmacogenetics and addiction. This search yielded 53 articles, of which 27 were selected. The most promising pharmacogenetic findings
Monthly injectable naltrexone for pathological gambling.
Gihyun Yoon et al.
The American journal of psychiatry, 170(6), 682-683 (2013-06-05)
T V Agibalova et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(6 Pt 2), 63-68 (2013-07-28)
This review of literature describes a role of chronic stress in the development of substance dependence including alcohol dependence. It is focused on neurochemical mechanisms of this dependence and approaches to its treatment in people with mental adaptation disorders. An
View All Related Papers

Articles

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service